Manipulating Y receptor subtype activation of short neuropeptide Y analogs by introducing carbaboranes

Neuropeptides

Volumn 47, Issue 2, 2013, Pages 59-66

  Hofmann, S ^a   Frank, R ^a   Hey Hawkins, E ^a   Beck Sickinger, A G ^a   Schmidt, P ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

1H NMR; G Protein coupled receptor; Neuropeptide Y analogs; Ortho Carbaborane

Indexed keywords

CARBABORANE DERIVATIVE; NEUROPEPTIDE Y [22-27]; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y4 RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; HUMAN; HUMAN CELL; HYDROPHOBICITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; BORANES; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; HEK293 CELLS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR SEQUENCE DATA; NEUROPEPTIDE Y; PROTEIN CONFORMATION; RECEPTORS, GASTROINTESTINAL HORMONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875252195     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2012.12.001     Document Type: Article

References (52)

1. ε-modified L-lysine into neuropeptide Y receptor Y1- and Y2-selective analogues. J. Med. Chem. 2011, 54:2368-2377.
2. Allen J., Novotny J., Martin J., Heinrich G. Molecular structure of mammalian neuropeptide Y: analysis by molecular cloning and computer-aided comparison with crystal structure of avian homologue. Proc. Natl. Acad. Sci. USA 1987, 84:2532-2536.
3. Balasubramaniam A., Ujhelyi M., Borchers M., Huang Y., Zhai W., Zhou Y., Johnson M., Sheriff S., Fischer J.E. Antagonistic properties of centrally truncated analogs of [D-Trp(32)]NPY. J. Med. Chem. 1996, 39:1142-1147.
4. Balasubramaniam A., Zhai W., Sheriff S., Tao Z., Chance W.T., Fischer J.E., Eden P., Taylor J. Bis(31/31') [Cys(31), Trp(32), Nva(34)]NPY (31-36)): a specific NPY Y-1 receptor antagonist. J. Med. Chem. 1996, 39:811-813.
5. Bax A.D., Davis D.G. Practical aspects of two-dimensional transverse NOE spectroscopy. J. Magn. Reson. 1985, 63:207-213.
6. Beck-Sickinger A.G., Jung G. Structure-activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors. Biopolymers 1995, 37:123-142.
7. Bellmann-Sickert K., Elling C.E., Madsen A.N., Little P.B., Lundgren K., Gerlach L.O., Bergmann R., Holst B., Schwartz T.W., Beck-Sickinger A.G. Long-acting lipidated analogue of human pancreatic polypeptide is slowly released into circulation. J. Med. Chem. 2011, 54:2658-2667.
8. Berridge M.J. Rapid accumulation of inositol trisphosphate reveals that agonists hydrolyse polyphosphoinositides instead of phosphatidylinositol. J. Biochem. 1983, 212:849-858.
9. Berridge M.J., Dawson R.M., Downes C.P., Heslop J.P., Irvine R.F. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. J. Biochem. 1983, 212:473-482.
10. Betzel T., Hess T., Waser B., Reubi J.C., Roesch F. Closo-Borane conjugated regulatory peptides retain high biological affinity: synthesis of closo-borane conjugated Tyr(3)-octreotate derivatives for BNCT. Bioconjug. Chem. 2008, 19:1796-1802.
11. Böhme I., Stichel J., Walther C., Mörl K., Beck-Sickinger A.G. Agonist induced receptor internalization of neuropeptide Y receptor subtypes depends on third intracellular loop and C-terminus. Cell. Signal. 2008, 20:1740-1749.
12. Bregadze V.I. Dicarba-closo-dodecaboranes C2B10H12 and their derivatives. Chem. Rev. 1992, 92:209-223.
13. Cabrele C., Beck-Sickinger A.G. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. J. Pept. Sci. 2000, 6:97-122.
14. 5-receptor increases food intake in rats. J. Biol. Chem. 2000, 275:36043-36048.
15. Cabrele C., Wieland H.A., Koglin N., Stidsen C., Beck-Sickinger A.G. Ala31-Aib32: identification of the key motif for high affinity and selectivity of neuropeptide Y at the Y5-receptor. Biochemistry 2002, 41:8043-8049.
16. Danho W., Triscari J., Vincent G., Nakajima T., Taylor J., Kaiser E.T. Synthesis and biological evaluation of pNPY fragments. Int. J. Pept. Protein Res. 1988, 32:496-505.
17. Daniels A.J., Matthews J.E., Slepetis R.J., Jansen M., Viveros O.H., Tadepalli A., Harrington W., Heyer D., Landavazo A., Leban J.J., Spaltenstein A. High-affinity neuropeptide Y receptor antagonists. Proc. Natl. Acad. Sci. USA 1995, 92:9067-9071.
18. Dumont Y., Martel J.C., Fournier A., St-Pierre S., Quirion R. Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog. Neurobiol. 1992, 38:125-167.
19. Dumont Y., Quirion R. [(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors. Br. J. Pharmacol. 2000, 129:37-46.
20. Herzog H., Hort Y.J., Ball H.J., Hayes G., Shine J., Selbie L.A. Cloned human neuropeptide Y receptor couples to two different second messenger systems. Proc. Natl. Acad. Sci. USA 1992, 89:5794-5798.
21. Kenakin, T., in press. New concepts in pharmacological efficacy at 7TM receptors. Brit. J. Pharmacol.
22. Korner M., Waser B., Reubi J.C. Neuropeptide Y receptor expression in human primary ovarian neoplasms. Lab. Invest. 2004, 84:71-80.
23. Korner M., Waser B., Reubi J.C. Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas. Int. J. Cancer 2005, 115:734-741.
24. Kostenis E. Is Gα16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors?. Trends Pharmacol. Sci. 2001, 22:560-564.
25. Larhammar D. Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Regul. Pept. 1996, 62:1-11.
26. Leban J.J., Heyer D., Landavazo A., Matthews J., Aulabaugh A., Daniels A.J. Novel modified carboxy terminal fragments of neuropeptide Y with high affinity for Y2-type receptors and potent functional antagonism at a Y1-type receptor. J. Med. Chem. 1995, 38:1150-1157.
27. Li R., Guan H., Yang K. Neuropeptide Y potentiates beta-adrenergic stimulation of lipolysis in 3T3-L1 adipocytes. Regul. Pept. 2012, 178:16-20.
28. Lindner D., Stichel J., Beck-Sickinger A.G. Molecular recognition of the NPY hormone family by their receptors. Nutrition 2008, 24:907-917.
29. Lindner D., van Dieck J., Merten N., Morl K., Gunther R., Hofmann H.J., Beck-Sickinger A.G. GPC receptors and not ligands decide the binding mode in neuropeptide Y multireceptor/multiligand system. Biochemistry 2008, 47:5905-5914.
30. Lindner D., Walther C., Tennemann A., Beck-Sickinger A.G. Functional role of the extracellular N-terminal domain of neuropeptide Y subfamily receptors in membrane integration and agonist-stimulated internalization. Cell. Signal. 2009, 21:61-68.
31. Liu M., Mao X., Ye C., Huang H., Nicholson J.K., Lindon J.C. Improved WATERGATE pulse sequences for solvent suppression in NMR spectroscopy. J. Magn. Reson. 1998, 125-129.
32. Lundell I., Blomqvist A.G., Berglund M.M., Schober D.A., Johnson D., Statnick M.A., Gadski R.A., Gehlert D.R., Larhammar D. Cloning of a human receptor of the NPY receptor family with high affinity for pancreatic polypeptide and peptide YY. J. Biol. Chem. 1995, 270:29123-29128.
33. Merten N., Lindner D., Rabe N., Rompler H., Morl K., Schoneberg T., Beck-Sickinger A.G. Receptor subtype-specific docking of Asp(6.59) with C-terminal arginine residues in Y receptor ligands. J. Biol. Chem. 2007, 282:7543-7551.
34. Michel M.C., Beck-Sickinger A., Cox H., Doods H.N., Herzog H., Larhammar D., Quirion R., Schwartz T., Westfall T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 1998, 50:143-150.
35. Mier W., Gabel D., Haberkorn U., Eisenhut M. Conjugation of the closo-borane mercaptoundecahydrododecaborate (BSH) to a tumour selective peptide. Z. Anorg. Allg. Chem. 2004, 630:1258-1262.
36. Moretto A., Crisma M., Formaggio F., Huck L.A., Mangion D., Leigh W.J., Toniolo C. Photoinduced intramolecular macrocyclization reaction between a Bpa and a Met residue in a helical peptide: 3D structures of the diastereomeric products. Chemistry 2009, 15:67-70.
37. Parker E.M., Babij C.K., Balasubramaniam A., Burrier R.E., Guzzi M., Hamud F., Mukhopadhyay G., Rudinski M.S., Tao Z., Tice M., Xia L., Mullins D.E., Salisbury B.G. GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists. Eur. J. Pharmacol. 1998, 349:97-105.
38. Pedrazzini T., Pralong F., Grouzmann E. Neuropeptide Y: the universal soldier. Cell. Mol. Life Sci. 2003, 60:350-377.
39. Reubi J.C., Gugger M., Waser B., Schaer J.C. Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res. 2001, 61:4636-4641.
40. Reubi J.C., Korner M., Waser B., Mazzucchelli L., Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur. J. Nucl. Med. Mol. Imaging 2004, 31:803-810.
41. Rosmaninho-Salgado J., Cortez V., Estrada M., Santana M.M., Goncalves A., Marques A.P., Cavadas C. Intracellular mechanisms coupled to NPY Y(2) and Y(5) receptor activation and lipid accumulation in murine adipocytes. Neuropeptides 2012, 46:359-366.
42. Schirrmacher E., Schirrmacher R., Beck C., Mier W., Trautman N., Rösch F. Synthesis of a Tyr3-octreotate conjugated closo-carborane [HC2B10H10]: a potential compound for boron neutron capture therapy. Tetrahedron Lett. 2003, 44:9143-9145.
43. Schober D.A., Van Abbema A.M., Smiley D.L., Bruns R.F., Gehlert D.R. The neuropeptide Y Y1 antagonist, 1229U91, a potent agonist for the human pancreatic polypeptide-preferring (NPY Y4) receptor. Peptides 1998, 19:537-542.
44. Schwartz T.W. Pancreatic polypeptide: a hormone under vagal control. Gastroenterology 1983, 85:1411-1425.
45. Tatemoto K., Carlquist M., Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982, 296:659-660.
46. Umezawa N., Noro Y., Ukai K., Kato N., Higuchi T. Photocontrol of peptide function: backbone cyclization strategy with photocleavable amino acid. Chembiochem 2011, 12:1694-1698.
47. Wheatley M., Wootten D., Conner M.T., Simms J., Kendrick R., Logan R.T., Poyner D.R., Barwell J. Lifting the lid on GPCRs: the role of extracellular loops. Br. J. Pharmacol. 2012, 165:1688-1703.
48. Wynne K., Stanley S., McGowan B., Bloom S. Appetite control. J. Endocrinol. 2005, 184:291-318.
49. Yulyaningsih E., Zhang L., Herzog H., Sainsbury A. NPY receptors as potential targets for anti-obesity drug development. Br. J. Pharmacol. 2011, 163:1170-1202.
50. Zhang L., Bijker M.S., Herzog H. The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol. Ther. 2011, 131:91-113.
51. Zwanziger D., Bohme I., Lindner D., Beck-Sickinger A.G. First selective agonist of the neuropeptide Y1-receptor with reduced size. J. Pept. Sci. 2009, 15:856-866.
52. Zwanziger D., Khan I.U., Neundorf I., Sieger S., Lehmann L., Friebe M., Dinkelborg L., Beck-Sickinger A.G. Novel chemically modified analogues of neuropeptide Y for tumor targeting. Bioconjug. Chem. 2008, 19:1430-1438.